BioNexus Gene Lab Corp.

NASDAQ: BGLC · Real-Time Price · USD
5.41
-0.16 (-2.87%)
At close: Aug 14, 2025, 3:58 PM
5.30
-2.03%
Pre-market: Aug 15, 2025, 07:14 AM EDT

BioNexus Gene Lab Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
9.51M 9.77M 10.93M 13.36M
Cost of Revenue
8.22M 8.44M 9.67M 11.17M
Gross Profit
1.29M 1.33M 1.26M 2.19M
Operating Income
-1.57M -2.59M -291.18K 1.06M
Interest Income
147.64K n/a n/a n/a
Pretax Income
-1.59M -2.61M -303.66K 1.04M
Net Income
-1.6M -2.63M -355.97K 751.57K
Selling & General & Admin
4M 3.04M 1.73M 1.2M
Research & Development
47.51K n/a n/a n/a
Other Expenses
n/a 379.19K -179.28K -66.49K
Operating Expenses
2.86M 3.92M 1.55M 1.14M
Interest Expense
21.15K 13.93K 12.48K 12.97K
Selling & Marketing Expenses
2.03M 596.86K n/a n/a
Cost & Expenses
8.21M 12.36M 11.22M 12.31M
Income Tax Expense
3.49K 21.53K 52.31K 291.28K
Shares Outstanding (Basic)
1.78M 1.72M 1.44M 1.43M
Shares Outstanding (Diluted)
1.78M 1.72M 1.44M 1.43M
EPS (Basic)
-0.09 -1.53 -0.02 0.05
EPS (Diluted)
-0.09 -1.53 -0.02 0.05
EBITDA
-1.42M -2.49M -185.76K 1.16M
EBIT
-1.57M -2.59M -291.18K 1.06M
Depreciation & Amortization
153.14K 108.42K 105.42K 108.22K